Loading stock data…
MDT
$81.98+1.29 (+1.60%)
After Hours$82.10+0.12 (+0.15%)· Last close Jun 9
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medtronic plc in the Healthcare sector is trading at $81.98 with a market capitalization of $100.1B. Wall Street consensus targets $98.58 (26 analysts), implying a +20.2% move over the next 12 months. The stock is currently 23% below its 52-week high of $106.33, remaining 10.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$81.98
Potential Upside
21%
Whystock Fair Value$99.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus26 analysts
Buy
Mean target$98.58+20.2%
Range$78.00 – $121.00
Fundamentals
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable car...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$100.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.87%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.42%
Volume
Today's trading volume
7.56M
Recent News
Goldman Sachs Reinstates Coverage of Medtronic (MDT)
Medtronic plc (NYSE:MDT) is one of the best healthcare stocks to buy with highest upside potential. On May 21, Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT) with a Neutral rating and set a $84 price target on the stock, which offers 7.5% upside potential. The firm told investors in a research note that the […]
Medtronic Expands Pain Care And Monitoring While Shares Trade Below Targets
Medtronic (NYSE:MDT) agreed to acquire SPR Therapeutics to expand its chronic pain care offerings with minimally invasive neuromodulation treatments. The company also secured FDA clearance for its Nellcor pulse oximetry system, which includes advanced signal processing aimed at more accurate readings across diverse patient groups. Medtronic enters this news cycle with its stock at $80.69, after a gain of 9.1% over the past week and 6.0% over the past 30 days. Despite these shorter term...
Medtronic set for Stealth AXiS expansion in Europe
With the CE mark for ear, nose and throat procedures, the advanced surgical navigation platform will be available to more surgeons across the region.
Medtronic gets FDA nod for updated pulse oximetry system
The changes support accuracy across diverse patient populations, skin tones and clinical care settings.
Best Long-Term Investment Stocks to Buy
The best long-term investment stocks are characterized by solid financial standing, consistent dividend growth and steady buybacks of their own shares.